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Background: The clinical manifestations of CF can be wide-ranging and often require a variety
of treatments administered by multi-disciplinary teams. Long-term management of CF is related to
disease severity and complications and impacts the costs associated with treatment of CF.
Objective: To describe clinical characteristics and evaluate resource use in clinical practice by CF
genotype.
Methods: A retrospective chart review of 200 patients (pts) 6 years of age with CF and the
G551D/other or DF508/DF508 mutation (genotypes that represent nearly 60% of UK pts) selected
from four adult and four paediatric CF centres was performed. Each centre contributed 25 pts,
including all G551D/other pts and randomly-selected DF508/DF508 pts. For each pt, the most recent
two years of eligible, uninterrupted resource use and clinical data were collected. Data from June
2007 to March 2012 were used.
Results: See Tables.
Conclusion: These pts with CF had a pattern of high resource use, including multiple hospitaliza-
tions and the administration of polypharmacy. Resource use was similar across G551D/other and
DF508/DF508 genotypes, despite some differences in clinical characteristics.
Patient characteristics at initial data point
Age Mean
(SD)
Gender
% Female
FEV1%
Mean (SD)
% PA culture
positive
% Pancreatic
insufﬁcient
Nutrition (Wt/age
z score) Mean
(SD)
% CFRD
positive
G551D/other (n = 63) 23.5 (11.8) 48 64.6 (22.7) 54 90 0.33 (1.1) 13
DF508/DF508 (n = 137) 17.7 (9.4) 50 69.4 (24.3) 49 96 −0.21 (1.0) 16
Healthcare utilization over two years
Routine Visits
Mean (SD)
No. of Hospns
Mean (SD)
Total No. of
Hosp days
Mean (SD)
Hosp
IV days
Mean
(SD)
Home
IV days
Mean
(SD)
Neb AB
n (%)
Dornase
n (%)
G551D/other
(pts, n = 63)
14.0 (8.4) 3.4 (3.4) 49 (82) 35 (40) 45 (80) 55 (87) 42 (67)
DF508/DF508
(pts, n = 137)
15.7 (9.3) 3.5 (3.3) 48 (84) 39 (46) 33 (49) 119 (87) 98 (72)
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and central Portugal and islands
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Objectives: To characterize the population of patients with cystic ﬁbrosis followed
at pediatric centers on the central and southern regions of Portugal and islands
(Azores and Madeira).
Methods: Collection of data from the data bases of all the cystic ﬁbrosis pediatric
centers in these regions. Patients in follow-up during 2012 were included.
Conclusion and Results: 139 patients (pts) were identiﬁed: 62 (44.6%) males, 2
with less than 1 year (y), 6 aged 1−2 y, 11 aged 3−5 y, 41 aged 6−10 y and 79 older
than 11 y. F508del mutation is the commonest one: 77 pts (55.4%) homozygous
and 62 (44.6%) heterozygous. Other more common mutations found are: G542X
(4.8% of the alleles), A561E (3.8%), R1066C and R334W (2.7% each) and N1303K
(2.2%).
Age of diagnosis varied between prenatal and 16 y: 67 pts were diagnosed under
1 y of age, 24 at 1−2 y, 13 at 3−5 y, 20 at 6−10 y and 8 older than 11 y. This last
group includes 2 pts f508 homozygous.
Comments: Only 6 mutations have been found in more than 1 or 2 pts. Several pts,
including some with classic mutations, have been diagnosed at a late age. Neonatal
screening could lead to a signiﬁcantly earlier diagnosis in this population.
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In June 2010, the First National Reference Center for Diagnosis and Treatment of
Patients with Cystic Fibrosis was created. An algorithm for mandatory newborn
screening was incorporated: an inmuno-reactive trypsin test (IRT/IRT) on dried
blood spot followed by a by sweat test and molecular analysis.
Aim: To assess a genotyping, and to calculate the frequencies of mutation distri-
bution in a population of probable or conﬁrmed CF patients.
Methods: From 2010 to 2012, blood samples were processed either coming from
newborn screening or from patients attending the CF Reference Center. Additionally
we analyzed the frequency of the mutation in 100 unrelated DF508 healthy controls.
Genomic DNA was extracted from peripheral blood lymphocytes, by Qiagen Dneasy
Blood and Tissue kit. The panel was chosen based on the known mutations of
patients diagnosed at that time. The selected panel covered over 95% of the
mutations found ethnic added to epidemiology.
Results: Of the 126 DNA analyzed we found that only 60 had two (48.3%)
or one (51.7%) of the mutations sought. The most frequent allele was DF508
(42.5%), followed by G542X (5.8%) and R334W (5.0%). The N1303K, W1282X,
R1162X, 2183AA>G, 3120+1G>A, 1078delT, R117H and 5T alleles appeared with
a frequency less than 2.5%.
Conclusions: We could achieve a mutational diagnosis in only the 23% of patients.
This could be due to false positive diagnosed CF patients or the mutational panel
was not the appropriated one. In the patients identiﬁed by the screening protocol and
diagnosed by a positive sweat test, without or with only one mutation, a complete
CFTR sequencing will be performed.
16 The −765G>C and 8473T>C polymorphism in COX2 gene and
57460C>T polymorphism in IFRD1 gene as modiﬁers of cystic
ﬁbrosis severity
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Objectives: To verify the association between the −765G>C and 8473T>C poly-
morphism in COX2 gene and 57460C>T polymorphism in IFRD1 gene with the
Cystic Fibrosis (CF) severity.
Methods: 103 patients were included, 55 were female and 97 Caucasians. Clinical
variables: sex, race, scores [Shwachman-Kulczycki, Kanga and Bhalla], BMI,
patient age, age at diagnosis, initial symptoms (digestive and pulmonary), ﬁrst
colonization by Pseudomonas aeruginosa, microorganisms [P. aeruginosa and
mucoid non-mucoid, Achromobacter xylosoxidans (AX), Staphylococcus aureus,
Burkolderia cepacia (BC)], SaO2, spirometry and comorbidities [nasal polyps, os-
teoporosis, meconium ileus (MI), pancreatic insufﬁciency, diabetes mellitus (DM)].
Statistical analysis was performed using SPSS v.17.0, Open Epi v.5.0 and the
R version 2.12. Data were compared by different tests according to the data
distribution. Data were compared using chi square test and Fisher exact test. For all
analyzes, we adopted alpha = 0.05. The CFTR mutations were used in the analysis
in association with the polymorphisms. There was not found association, except for
meconium ileus (p = 0.028 − in patients with two CFTR mutations from class I, II
and III) and for nasal polyposis (p = 0.022 − in patients whose CFTR genotype was
not considered) to the 8473T>C polymorphism in COX2 gene with odds ratio of
5.552 (95 IC: 1.318–38.27) and 5.486 (95 IC: 1.192−40) to CC + GC, respectively.
Conclusion: The 8473T>C polymorphism in the COX2 gene is a possible modiﬁer
gene of CF.
